Table 3.
Association between HIV clinical data and HIV infection type
| Clinical data | Description | HIV1 mono-infection (n = 68) |
HIV1/HBV co-infection (n = 22) |
p-value |
|---|---|---|---|---|
| Median (IQR) | ||||
| Hb (g/dL) | 10. 0 (8.5–11.8) | 10.4 (8.8–11.4) | 0.917 | |
| PLT (109/L) | 208 (165.0–245.0) | 230 (167.3–256.3) | 0.460 | |
| ALT (U/L) | 28.1(18.1–34.7) | 25.6 (17.3–45.3) | 0.821 | |
| AST (U/L) | 30.6 (23.8–45.0) | 33.0 (27.5–58.9) | 0.123 | |
| Creatinine (mg/dL) | 80.0 (65.1–106.2) | 89.8 (62.0–118.2) | 0.351 | |
| ALT (U/L) | Hepatotoxicity, n (%) | |||
| Absent | < 50.0 | 64 (91.4) | 19 (86.4) | 0.355 |
| Present | ≥ 50.0 | 4 (5.9) | 3 (13.6) | |
| Grade 1 | 50.0–99.9 | 4 (5.9) | 1 (4.5) | 0.042 |
| Grade 2 | 100.0–199.9 | 0 (0.0) | 2 (9.1) | |
| Grade 3 and 4 | ≥ 200.0 | 0 (0.0) | 0 (0.0) | |
| APRI | Liver fibrosis, n (%) | |||
| Absent | < 1.5 | 67 (98.5) | 21 (95.5) | 0.431 |
| Present | > 1.5 | 1 (1.5) | 1 (4.5) | |
| eGFR (mL/min/1.73 m2) | CKD, n (%) | |||
| Absent | ≥ 60 | 58 (85.3) | 18 (81.8) | 0.696 |
| Present | < 60 | 10 (14.7) | 4 (18.2) | |
| Stage 1 |
≥ 90 Normal GFR |
40 (58.8) | 10 (45.5) | 0.053 |
| Stage 2 |
60–89 Mildly reduced GFR |
18(26.5) | 8 (36.4) | |
| Stage 3 |
30–59 Moderately reduced GFR |
10 (14.7) | 2 (9.1) | |
| Stage 4 |
15–29 Severely reduced GFR |
0 (0.0) | 2 (9.1) | |
| n (%) | ||||
| HIV stages | Stage 1 | 47 (52.2) | 17 (18.9) | 0.86 |
| Stage 2 | 10 (11.1) | 3 (3.3) | ||
| Stage 3 | 6 (6.7) | 1 (1.1) | ||
| Stage 4 | 5 (5.6) | 1 (1.1) | ||
Mann–Whitney test was used to compare levels of Hb, PLT, ALT and AST. Where IQR = interquartile range. Association analyses of infection type with hepatotoxicity, liver fibrosis CKD or HIV stages were done using Pearson’s Chi-square test or Fisher’s exact test. A two-tailed p-value was considered significant at p < 0.05